Dr. Childs formed Renovo Research in 2008. Dr. Childs brings over two decades of experience in crystal engineering to Renovo and was a pioneer in the field of pharmaceutical cocrystals. Dr. Childs developed the screening platform that is used at Renovo to discover new crystal forms of active pharmaceutical ingredients. Dr. Childs has a unique mix of management, operational, and scientific experience that complements the mission of Renovo.
Three of the top seven most cited primary literature manuscripts on pharmaceutical cocrystals were authored by Dr. Childs.
For additional information, see Dr. Childs' Linked in profile.
Renovo has played an active role in the development of the field of pharmaceutical cocrystals during the last decade, publishing over 25 articles and patent applications ... Four representative articles are highlighted below:
The Salt-Cocrystal Continuum: The Influence of Crystal Structure on Ionization State
Molecular Pharmaceutics, 2007, 4 (3), pp 323–338April 26, 2007
Authors: Scott Childs, G. Patrick Stahly, Aeri Park
Salts and cocrystals are multicomponent crystals that can be distinguished by the location of the proton between an acid and a base. At the salt end of the spectrum proton transfer is complete, and on the opposite end proton transfer is absent in cocrystals... more
Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine
CrystEngComm, 2008, 10, 856March 20, 2008
Authors: Scott Childs, Naír Rodríguez-Hornedo, L.Sreenivas Reddy, et al.
Four different screening techniques were used to form cocrystals of carbamazepine containing pharmaceutically acceptable carboxylic acids. Twenty-seven unique solid phases utilizing eighteen carboxylic acid coformers were generated in the screening experiments... more
Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids
Journal of the American Chemical Society (2004), 126(41), 13335-42.August 24, 2004
Authors: Scott Childs, G. Patrick Stahly, Barbara C. Stahly, Leonard J. Chyall
A crystal engineering strategy for designing cocrystals of pharmaceuticals is presented. The strategy increases the probability of discovering useful cocrystals and decreases the number of experiments that are needed by selecting API:guest combinations that have the greatest potential of forming... more
Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API
Pharmaceutical Research (2006), 23(8), 1888-1897April 9, 2006
Authors: Scott Childs, Daniel P. McNamara
The bioavailability of a development candidate active pharmaceutical ingredient (API) was very low after oral dosing in dogs. In order to improve bioavailability, we sought to increase the dissolution rate of the solid form of the API. When traditional methods of forming salts and amorphous material failed to produce a viable solid form for continued development, we turned to cocrystals... more